NO20050540L - Krystallinske former av kinoxalin-2-karboksylsyre [4-karbamT-1-(3-fluorbenzyl)-2,7-dihydroksy-7-metyloktyl]-ami - Google Patents
Krystallinske former av kinoxalin-2-karboksylsyre [4-karbamT-1-(3-fluorbenzyl)-2,7-dihydroksy-7-metyloktyl]-amiInfo
- Publication number
- NO20050540L NO20050540L NO20050540A NO20050540A NO20050540L NO 20050540 L NO20050540 L NO 20050540L NO 20050540 A NO20050540 A NO 20050540A NO 20050540 A NO20050540 A NO 20050540A NO 20050540 L NO20050540 L NO 20050540L
- Authority
- NO
- Norway
- Prior art keywords
- methyloctyl
- fluorobenzyl
- dihydroxy
- carboxylic acid
- carbam
- Prior art date
Links
- 125000006284 3-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(F)=C1[H])C([H])([H])* 0.000 title 1
- 150000001412 amines Chemical class 0.000 title 1
- UPUZGXILYFKSGE-UHFFFAOYSA-N quinoxaline-2-carboxylic acid Chemical compound C1=CC=CC2=NC(C(=O)O)=CN=C21 UPUZGXILYFKSGE-UHFFFAOYSA-N 0.000 title 1
- RALCLUSHFOIHOL-UHFFFAOYSA-N 5-amino-6-(3-fluorophenyl)-4-hydroxy-2-(3-hydroxy-3-methylbutyl)hexanamide Chemical compound CC(C)(O)CCC(C(N)=O)CC(O)C(N)CC1=CC=CC(F)=C1 RALCLUSHFOIHOL-UHFFFAOYSA-N 0.000 abstract 1
- 102100031172 C-C chemokine receptor type 1 Human genes 0.000 abstract 1
- 101710149814 C-C chemokine receptor type 1 Proteins 0.000 abstract 1
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- 239000013078 crystal Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40321602P | 2002-08-12 | 2002-08-12 | |
| PCT/IB2003/003464 WO2004014875A1 (en) | 2002-08-12 | 2003-07-31 | Crystal forms of quinoxaline-2-carboxylic acid [4-carbamoyl-1-(3-fluorobenzyl)-2,7-dihydroxy-7-methyl-octyl]-amide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20050540L true NO20050540L (no) | 2005-03-10 |
Family
ID=31715961
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20050540A NO20050540L (no) | 2002-08-12 | 2005-01-31 | Krystallinske former av kinoxalin-2-karboksylsyre [4-karbamT-1-(3-fluorbenzyl)-2,7-dihydroksy-7-metyloktyl]-ami |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20040072834A1 (es) |
| EP (1) | EP1539715A1 (es) |
| JP (1) | JP2005538130A (es) |
| AP (1) | AP2005003226A0 (es) |
| AR (1) | AR040839A1 (es) |
| AU (1) | AU2003250450A1 (es) |
| BR (1) | BR0313378A (es) |
| CA (1) | CA2494776A1 (es) |
| EC (1) | ECSP055588A (es) |
| GT (1) | GT200300169A (es) |
| IL (1) | IL166548A0 (es) |
| IS (1) | IS7674A (es) |
| MX (1) | MXPA05001781A (es) |
| NO (1) | NO20050540L (es) |
| OA (1) | OA12894A (es) |
| PA (1) | PA8580401A1 (es) |
| PE (1) | PE20040866A1 (es) |
| TN (1) | TNSN05035A1 (es) |
| TW (1) | TW200407316A (es) |
| UY (1) | UY27928A1 (es) |
| WO (1) | WO2004014875A1 (es) |
| ZA (1) | ZA200500768B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011079007A1 (en) | 2009-12-23 | 2011-06-30 | Ironwood Pharmaceuticals, Inc. | Crth2 modulators |
| US20130216552A1 (en) | 2010-07-12 | 2013-08-22 | Ironwood Pharmaceuticals, Inc. | Crth2 modulators |
| WO2012009134A1 (en) | 2010-07-12 | 2012-01-19 | Ironwood Pharmaceuticals, Inc. | Crth2 modulators |
| CN102276539B (zh) * | 2011-06-29 | 2013-08-14 | 赵雪梅 | 一种具有抑菌作用的化合物及其制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE640616A (es) * | 1962-12-19 | |||
| US3492397A (en) * | 1967-04-07 | 1970-01-27 | Warner Lambert Pharmaceutical | Sustained release dosage in the pellet form and process thereof |
| US4060598A (en) * | 1967-06-28 | 1977-11-29 | Boehringer Mannheim G.M.B.H. | Tablets coated with aqueous resin dispersions |
| US3538214A (en) * | 1969-04-22 | 1970-11-03 | Merck & Co Inc | Controlled release medicinal tablets |
| US4173626A (en) * | 1978-12-11 | 1979-11-06 | Merck & Co., Inc. | Sustained release indomethacin |
| PL335484A1 (en) * | 1997-02-26 | 2000-04-25 | Pfizer | Derivatives of heteroarylhexamide, their production and application as selective inhibitors of mip-1a being assimilated by its ccr1 receptor |
| TR200002248T2 (tr) * | 1998-02-05 | 2000-12-21 | Pfizer Products Inc. | Yeni dihidroksiheksanoik asit türevleri |
-
2003
- 2003-07-31 MX MXPA05001781A patent/MXPA05001781A/es not_active Application Discontinuation
- 2003-07-31 AP AP2005003226A patent/AP2005003226A0/xx unknown
- 2003-07-31 BR BR0313378-8A patent/BR0313378A/pt not_active Application Discontinuation
- 2003-07-31 AU AU2003250450A patent/AU2003250450A1/en not_active Abandoned
- 2003-07-31 OA OA1200500028A patent/OA12894A/en unknown
- 2003-07-31 WO PCT/IB2003/003464 patent/WO2004014875A1/en not_active Application Discontinuation
- 2003-07-31 JP JP2004527195A patent/JP2005538130A/ja active Pending
- 2003-07-31 EP EP03784383A patent/EP1539715A1/en not_active Withdrawn
- 2003-07-31 CA CA002494776A patent/CA2494776A1/en not_active Abandoned
- 2003-08-05 UY UY27928A patent/UY27928A1/es not_active Application Discontinuation
- 2003-08-06 GT GT200300169A patent/GT200300169A/es unknown
- 2003-08-06 TW TW092121503A patent/TW200407316A/zh unknown
- 2003-08-08 US US10/637,475 patent/US20040072834A1/en not_active Abandoned
- 2003-08-08 PE PE2003000794A patent/PE20040866A1/es not_active Application Discontinuation
- 2003-08-08 AR AR20030102881A patent/AR040839A1/es unknown
- 2003-08-12 PA PA20038580401A patent/PA8580401A1/es unknown
-
2005
- 2005-01-26 ZA ZA200500768A patent/ZA200500768B/xx unknown
- 2005-01-27 IS IS7674A patent/IS7674A/is unknown
- 2005-01-27 IL IL16654805A patent/IL166548A0/xx unknown
- 2005-01-31 NO NO20050540A patent/NO20050540L/no unknown
- 2005-02-03 EC EC2005005588A patent/ECSP055588A/es unknown
- 2005-02-11 TN TNP2005000035A patent/TNSN05035A1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| UY27928A1 (es) | 2004-03-31 |
| PA8580401A1 (es) | 2004-02-16 |
| TW200407316A (en) | 2004-05-16 |
| MXPA05001781A (es) | 2005-04-25 |
| EP1539715A1 (en) | 2005-06-15 |
| WO2004014875A1 (en) | 2004-02-19 |
| PE20040866A1 (es) | 2004-11-26 |
| OA12894A (en) | 2006-10-13 |
| GT200300169A (es) | 2004-05-12 |
| AP2005003226A0 (en) | 2005-03-31 |
| IL166548A0 (en) | 2006-01-15 |
| US20040072834A1 (en) | 2004-04-15 |
| JP2005538130A (ja) | 2005-12-15 |
| BR0313378A (pt) | 2005-07-12 |
| AR040839A1 (es) | 2005-04-20 |
| CA2494776A1 (en) | 2004-02-19 |
| ECSP055588A (es) | 2005-04-18 |
| ZA200500768B (en) | 2006-07-26 |
| AU2003250450A1 (en) | 2004-02-25 |
| IS7674A (is) | 2005-01-27 |
| TNSN05035A1 (fr) | 2007-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2007059257A3 (en) | N4-phenyl-quinaz0line-4 -amine derivatives and related compounds as erbb type i receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases | |
| WO2003057698A3 (en) | Spiroazacyclic compounds as monoamine receptor modulators | |
| WO2005021536A3 (en) | Adamantane and azabicyclo-octane and nonane derivatives, process of their preparation and their use as dpp-iv inhibitors | |
| WO2004022537A3 (en) | Thienopyrrolyl and furanopyrrolyl compounds and their use as histamine h4 receptor ligands | |
| CA2443724A1 (en) | Novel, arylsusfonamide compounds for the treatment of obesity, type ii diabetes and cns-disorders | |
| WO2002098865A3 (fr) | Inhibiteurs des phosphodiesterases des nucleotides cycliques, preparation et utilisations de ces inhibiteurs | |
| UA87856C2 (ru) | Алкильные производные как модуляторы метаботропных рецепторов глутамата | |
| TW200407305A (en) | Novel compounds | |
| WO2006073973A3 (en) | Novel benzylamine derivatives as cetp inhibitors | |
| WO2005108358A3 (en) | Pyrrolidine derivatives useful as bace inhibitors | |
| NO20051503L (no) | Pyrazolopyridiner og fremgangsmater for fremstilling og anvendelse av de samme. | |
| NO20082136L (no) | 1,5-substituerte indol-2-yl-amidderivater | |
| WO2004094386A8 (en) | Isoquinoline-5-sulfonic acid amides as inhibitors of akt (protein kinase b) | |
| MY141528A (en) | Anilinopyrazole derivatives useful for the treatment of diabetes | |
| NO20061575L (no) | Fremgangsmate for fremstilling av renzapride og mellomprodukter derav | |
| WO2004084943A8 (en) | Use of antagonists of ghrelin or ghrelin receptor to treat intestinal inflammation | |
| NO20050540L (no) | Krystallinske former av kinoxalin-2-karboksylsyre [4-karbamT-1-(3-fluorbenzyl)-2,7-dihydroksy-7-metyloktyl]-ami | |
| WO2007119120A3 (en) | Crystalline polymorphic forms of olopatadine hydrochloride and processes for their preparation | |
| WO2006089286A3 (en) | Triazadibenzoazulene compounds useful for the treatment and prevention of pain and screening methods therefor compounds useful for the treatment and prevention of pain and screening methods therefor | |
| WO2004052858A3 (en) | Inhibitors of monoamine uptake | |
| WO2004019879A8 (en) | Motilide compounds | |
| WO2003072537A3 (en) | Selective protein tyrosine phosphatatase inhibitors | |
| WO2003072572A8 (en) | Beta3-adrenergic receptor agonists | |
| EA200602081A1 (ru) | Пиридиновые производные алкилоксиндолов в качестве агентов, активных в отношении рецептора 5-нт7 | |
| EP1801232A4 (en) | METHOD FOR SORTING TRANSMEMBRANE ENZYME INHIBITOR SUBSTANCE |